Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;62(9):2169-2176.
doi: 10.1080/10428194.2021.1910686. Epub 2021 May 21.

Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials

M Lia Palomba  1 , Monika Parisi Jun  2 , James Lymp  3 , Andy Nguyen  4 , November McGarvey  4 , Matthew Gitlin  4 , Corey Pelletier  2 , Scott J Keating  2 , John Godwin  5
Affiliations

Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials

M Lia Palomba et al. Leuk Lymphoma. 2021 Sep.

Abstract

This retrospective study estimated postinfusion health care resource utilization (HCRU) by site of care among 303 patients with relapsed/refractory large B-cell lymphoma who received third- or later-line treatment with lisocabtagene maraleucel (liso-cel) in the TRANSCEND NHL 001 and OUTREACH trials. Inpatients (n = 256) had higher rates of hospitalization versus outpatients (n = 47; >99% vs 62%), by definition, and higher rates of tocilizumab use for cytokine release syndrome and/or neurological events (22% vs 9%). Rates of intensive care unit admission, corticosteroid use, vasopressor use, hemodialysis, and intubation were generally low and similar between groups. Median (range) total hospital length of stay was 15 (0-88) days (inpatients) and 4 (0-77) days (outpatients). Over 6 months, estimated mean postinfusion cost of care was $89,535 (inpatients) and $36,702 (outpatients). Most costs were incurred in the first month post infusion (inpatients, $50,369 [56%]; outpatients, $19,837 [54%]). Lower overall HCRU was observed with outpatient postinfusion monitoring.

Keywords: CAR T cell therapy; cost; economic burden; inpatient and/or outpatient monitoring; lisocabtagene maraleucel; resource utilization.

PubMed Disclaimer

Conflict of interest statement

Disclosure of interest

M. Lia Palomba reports personal fees and other from Merck, personal fees from Novartis, personal fees and other from Pharmacyclics, personal fees and other from Kite, personal fees from BeiGene, outside the submitted work; Dr. Palomba has intellectual property interests (by virtue of immediate family member interests) related to CARs (Chimeric Antigen Receptors) and TCRs (T cell Receptors) that Memorial Sloan Kettering Cancer Center (MSK) has licensed to Juno Therapeutics, a Bristol-Myers Squibb Company. Monika P. Jun, Scott Keating, James Lymp, and Corey Pelletier are employees of Bristol Myers Squibb and may hold stock in Bristol Myers Squibb. November McGarvey, Matthew Gitlin, and Andy Nguyen are employees of BluePath Solutions, which received funding from Bristol Myers Squibb, to conduct the analyses. John E. Godwin reports no conflict of interest.

Figures

Figure 1.
Figure 1.
Study methodology. HCRU can occur at any time point from the day of administration up to and including day 180 (light blue bars); individual “funnels” represent how costs are estimated at each 30-day interval. AE: adverse event; Liso-cel: lisocabtagene maraleucel.
Figure 2.
Figure 2.
Costs of care after lisocabtagene maraleucel administration by postinfusion monitoring site: (A) inpatient and (B) outpatient. The study protocol did not have scheduled visits at month 5. HCRU and costs that occurred in month 5 may be from scheduled month 4 or 6 visits in the protocol.
See this image and copyright information in PMC

References

    1. US Cancer Statistics Working Group. US Cancer Statistics Data Visualizations Tool, based on November 2018 submission data (1999-2016) [Internet]. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2019. [cited 2020 Oct 6]. Available from: https://gis.cdc.gov/Cancer/USCS/DataViz.html
    1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16(8):2780–2795. - PubMed
    1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89(11):3909–3918. - PubMed
    1. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11(1):12–23. - PMC - PubMed
    1. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808. - PMC - PubMed

Publication types

LinkOut - more resources